Routine-Dose and High-Dose Icotinib in Patients with Advanced Non–Small Cell Lung Cancer Harboring EGFR Exon 21-L858R Mutation: the Randomized, Phase II …
X Li, L Zhang, D Jiang, Y Wang, A Zang, C Ding… - Clinical Cancer …, 2020 - AACR
Purpose: Our primary purpose is to explore safety and efficacy of high-dose icotinib in
comparison with routine-dose icotinib in patients with non–small cell lung cancer (NSCLC) …
comparison with routine-dose icotinib in patients with non–small cell lung cancer (NSCLC) …
The effect of icotinib combined with chemotherapy in untreated non-small-cell lung cancer that harbored EGFR-sensitive mutations in a real-life setting: a retrospective …
L Wang, Y Li, L Li, Z Wu, D Yang, H Ma… - OncoTargets and …, 2018 - Taylor & Francis
Purpose This study was conducted to compare the efficacy of a combination of icotinib and
chemotherapy with icotinib or chemotherapy alone in untreated non-small cell lung cancer …
chemotherapy with icotinib or chemotherapy alone in untreated non-small cell lung cancer …
A single-arm, multicenter, safety-monitoring, phase IV study of icotinib in treating advanced non-small cell lung cancer (NSCLC)
X Hu, B Han, A Gu, Y Zhang, SC Jiao, C Wang, J He… - Lung Cancer, 2014 - Elsevier
Background The phase 3 ICOGEN trial established the non-inferiority of icotinib to gefitinib
in terms of progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients …
in terms of progression-free survival (PFS) in non-small cell lung cancer (NSCLC) patients …
Comparison of the efficacy of icotinib in patients with non‑small‑cell lung cancer according to the type of epidermal growth factor receptor mutation
ZX Xue, WX Wen, Y Zhuang… - Molecular and …, 2016 - spandidos-publications.com
Icotinib hydrochloride is a novel epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitor (TKI) with preclinical and clinical activity in non‑small‑cell lung cancer (NSCLC) …
inhibitor (TKI) with preclinical and clinical activity in non‑small‑cell lung cancer (NSCLC) …
Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: a multi‐center …
L Lei, W Wang, Y Zhu, J Li, Y Fang, H Wang… - Cancer …, 2020 - Wiley Online Library
The response to icotinib in advanced non‐small cell lung cancers (NSCLC) with EGFR
uncommon mutation (EGFRum) is unclear. Here we reported the efficacy and potential …
uncommon mutation (EGFRum) is unclear. Here we reported the efficacy and potential …
Study of anlotinib combined with icotinib as the first-line treatment in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations (ALTER-L004).
D Huang, D Zhong, C Zhang, Y Zhang, Y Shang… - 2020 - ascopubs.org
9573 Background: Anti-angiogenic monoclonal antibodies plus EGFR TKIs have previously
shown to prolong PFS in patients with EGFR-mutated NSCLC (JO25567 and NEJ026) …
shown to prolong PFS in patients with EGFR-mutated NSCLC (JO25567 and NEJ026) …
[HTML][HTML] Clinical efficacy of icotinib in lung cancer patients with different EGFR mutation status: a meta-analysis
J Qu, YN Wang, P Xu, DX Xiang, R Yang, W Wei… - Oncotarget, 2017 - ncbi.nlm.nih.gov
Icotinib is a novel and the third listed epidermal growth factor receptor-tyrosine kinase
inhibitors (EGFR-TKIs), which exerts a good anti-tumor efficacy on non-small cell lung …
inhibitors (EGFR-TKIs), which exerts a good anti-tumor efficacy on non-small cell lung …
[HTML][HTML] Osimertinib vs. afatinib as first-line treatment for patients with metastatic non-small cell lung cancer with an EGFR exon 19 deletion or exon 21 L858R mutation
S Gilardone, R Thapa, J Laborde… - Journal of Thoracic …, 2023 - ncbi.nlm.nih.gov
Background The optimal treatment sequencing for patients with metastatic epidermal growth
factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) remains a subject of …
factor receptor (EGFR)-mutant non-small cell lung cancer (NSCLC) remains a subject of …
Sequential treatment in advanced non–small cell lung cancer harboring EGFR mutations
PC Hsu, JWC Chang, CF Chang… - Therapeutic …, 2022 - journals.sagepub.com
Background: Epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) are
standard treatments for advanced EGFR-mutated non–small cell lung cancer (NSCLC) …
standard treatments for advanced EGFR-mutated non–small cell lung cancer (NSCLC) …
Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified.
Z Song, X Yu, J Cai, L Shao, B Lin… - Chinese Journal of …, 2013 - search.ebscohost.com
Background and objective As the first epidermal growth factor receptor tyrosine kinase
inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo …
inhibitor (EGFR-TKI) in China, icotinib shows promising anticancer activity in vitro and vivo …